China's National Medical Products Administration granted drug registration approval for Sihuan Pharmaceutical (HKG:0460) subsidiary Huisheng Biopharmaceutical's Dapagliflozin tablets for the treatment of type 2 diabetes in adult patients.
The medication also passed China's consistency evaluation of quality and efficacy of generic drugs, according to a Wednesday filing with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.